COMPLETED

Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial studies how well attention bias modification (ABM) improves anxiety in adolescent and young adult (AYA) cancer survivors. Cancer-related anxiety is the most prevalent mental health problem affecting AYA cancer survivors. Cancer-related anxiety is associated with long-term negative outcomes such as poor quality of life, depression, distress, substance use, sleep problems, fatigue, and pain. ABM uses techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. ABM uses brief self-guided smartphone applications. Patients complete repetitive association reaction-time tasks targeting automatic and unconscious negative attention biases to retrain attention away from perceived threat and towards a neutral or positive stimuli. Gratitude-finding and savoring activities are also provided to maintain and increase positive emotions. Using ABM plus gratitude-finding and savoring activities may improve anxiety in AYA cancer survivors.

Official Title

Anxiety and Negative Attentional Bias in Adolescent and Young Adult Cancer Survivors

Quick Facts

Study Start:2024-11-08
Study Completion:2026-01-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06682039

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 29 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 15-29 years
  2. * Diagnosis of cancer malignancy
  3. * Received active/curative cancer treatment OR received/actively receiving cancer survivorship care at Seattle Children's Hospital (SCH) or other study referring site (e.g. St. Jude)
  4. * Currently off active/curative cancer treatment
  5. * Patient able to understand/read/write English language
  6. * Cognitively able to participate in ABM intervention and complete surveys
  7. * Patient has access to smartphone able to send and receive text messages
  8. * Patient has access to computer or smartphone for Inquisit program
  1. * Patients on active/curative cancer treatment
  2. * Cognitively or physically unable to participate in ABM intervention and surveys
  3. * Patients who cannot understand/read/write English will be excluded from the research because the ABM intervention is currently only available in English
  4. * Furthermore, patients who do not have access to technology (smartphone/computer) will be excluded from the study as this technology is absolutely required to engage in the study intervention

Contacts and Locations

Principal Investigator

Nancy Lau, PhD
PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

Study Locations (Sites)

Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Fred Hutchinson Cancer Center

  • Nancy Lau, PhD, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-08
Study Completion Date2026-01-12

Study Record Updates

Study Start Date2024-11-08
Study Completion Date2026-01-12

Terms related to this study

Additional Relevant MeSH Terms

  • Childhood Hematopoietic and Lymphatic System Neoplasm
  • Childhood Malignant Solid Neoplasm